
Opinion|Videos|May 6, 2024
A New Era in PAH Treatment?
Author(s)Marius Hoeper, MD
An expert on pulmonary arterial hypertension discusses the potential impact of emerging therapies, including sotatercept, ralinepag, and inhaled imatinib.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What is your assessment of the potential clinical impact of new or emerging pulmonary arterial hypertension (PAH) therapies, such as sotatercept, ralinepag, and inhaled imatinib, in terms of reducing hospitalizations or need for supportive care and improving long-term patient outcomes and quality of life?
Advertisement
Related to this article

A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.

The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.

Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.

Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.

TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
Keynote Address Tackles AI’s Role in Health Care, Eye Care
3
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
4
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
5



